Ind-Swift Laboratories Ltd.

Established in 1995, Ind-Swift has fast evolved towards a business model that is focused on deep-rooted domestic presence and has leveraged on high-value mature regulated markets with considerable growth in emerging markets. With world class manufacturing sites, independent State-of-the-Art R&D Centre and Regulatory approvals, the Group has embarked upon a journey to establish itself as a reliable partner in the Global Pharmaceutical Industry. In house capabilities for Development of APIs, Finished Dosage forms, Non-Infringing Process & World Class facilities for Contract Manufacturing are our inherent strengths. Ind-Swift Laboratories Ltd. is ethically driven organization that believes in bringing positive change in the world. We have been able to persist in volatile industrial conditions by our determination to deliver products that consistently confirm global quality standards. ISLL has transformed itself into an integrated, state of the art pharmaceutical manufacturer and we are on a Journey to attain unmatched heights in Industry. We are a firm incorporated with an aim to cater to the global needs of a “healthy world” through our quality products and services provided to existing and potential customers. With hands on diverse Industrial Experience, our team serves the best pharmaceutical products, ingredients and solutions custom-tailored to every client’s specific business need.

Anthem Biosciences Limited

Anthem Biosciences, a Bangalore-India based Contract Research Development Organization (CDMO) Anthem Bio offers a whole gamut of services dedicated to enabling and sustaining global research efforts in the discovery of new compounds by pharmaceutical, biotechnology, specialty chemicals, agriculture chemicals and material science companies. Anthem's core competencies are organic synthesis, process development, analytical chemistry, discovery biology and regulatory compliance. Anthem works extensively with pharma leaders, mid-size to virtual companies across the globe.

Tirupati Group

Tirupati Group started its journey in 2005 with the vision to make healthcare accessible & amp; affordable for everyone. With continuous innovation and constant evolution, today Tirupati group has emerged to become one of the largest and fastest growing pharmaceutical leaders of India and across the globe. Having sophisticated R&D at its core, Tirupati Group brings novel and best-in class solutions to the market by merging cutting edge bio-technology with next generation innovation. Located at the foothill of Himachal Pradesh, India, our highly advanced, state-of-the-art facilities are recognized as the largest and excellently efficient manufacturer of end-to-end solutions. And all of our facilities ensure regulatory compliance by maintaining quality as per GLP standards. With 145 clients across 11 countries of the world, we have proudly expanded to cater to a broad array of major segments like Pharmaceuticals, Nutraceuticals, Ayurveda and a very niche segment like Sports Nutrition, where we contribute to more than 60% of the market share for generic protein powders in India. With a pledge to enhance the quality of life for everyone, we are committed to deliver the highest quality solutions with exemplary integrity.

Sai Life Sciences Ltd

Sai Life Sciences is built on the bedrock of partnership. We work with innovator pharma and biotech companies to accelerate the discovery, development and manufacture of complex small molecules for a healthier tomorrow. Our Vision is to support our global innovator partners bring 25 new medicines to life by 2025. And we are well on that journey.

Morepen Laboratories Limited India

Morepen is a market leader in glucometers, having installed over 12 million units to date and sold nearly 1.6 million blood glucose strips, driven by an aggressive market expansion strategy into tier-2 and tier-3 cities. As a leading manufacturer of BP monitors, the company has shown impressive growth in the Point of Care (POC) diagnostics segment. In the API business, Morepen holds a leadership position in the export of six key API products: Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine, catering to numerous international markets and exporting to over 80 countries. Approximately 68% of Morepen's API products are exported, highlighting its extensive global reach. The company has demonstrated consistent growth in both its top and bottom lines through strategic investments and market expansions. Morepen maintains a debt-free status with robust financials and a negligible interest burden, underscoring its financial stability. Founded in 1984, Morepen Laboratories Limited (www.morepen.com) has established itself as a prominent leader in the pharmaceutical industry, renowned for its high-quality products and innovative solutions. The company offers a diverse range of products, including active pharmaceutical ingredients, diagnostics, and over-the-counter items. Morepen is dedicated to enhancing global health through its advanced research and development efforts.